<DOC>
	<DOCNO>NCT00825253</DOCNO>
	<brief_summary>This trial conduct Europe . The aim clinical trial compare pharmacodynamics ( i.e . glucose-lowering effect study medication entire observation phase time administration efficacy period ) pharmacokinetics ( i.e . amount study insulin determine blood ) treatment biphasic insulin aspart 30 ( BiAsp 30 ) administer , twice thrice daily biphasic human insulin 30 administer daily type 2 diabetic subject</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics Biphasic Insulin Aspart 30 Biphasic Human Insulin 30 Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart , insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject ) Type 2 diabetes mellitus diagnose least 12 month prior screen HbA1c value 7 % 10.5 % ( inclusive ) screen Any insulin treatment least 3 month prior screen Body mass index ( BMI ) : 25 40 kg/m2 Use oral antidiabetic agent within past 6 month Active proliferative retinopathy maculopathy require treatment within 6 month prior screen Cardiac disease : NYHA class III IV chronic heart failure ( CHF ) , unstable angina , and/or myocardial infarction ( treat untreated ) within 6 month prior screen Hepatic insufficiency ( ALT AST great equal 2 time central laboratory 's upper reference limit ) Renal insufficiency ( serum creatinine great equal 1.6 mg/dL male ; great equal Recurrent hypoglycaemia hypoglycaemic unawareness Anaemia ( haemoglobin le 13.0 mg/dL male less 12.0 mg/dL female ) ( WHO criteria ) Use systemic topical medication ( prescribed nonprescribed ) may alter glucose metabolism ( insulin product ) , include limited : systemic inhaled glucocorticoid , anabolic steroid , nonselective betablockers History substance ( e.g . drug , alcohol ) abuse positive result urine drug/alcohol screen consumption 14 unit ( woman ) 21 unit ( men ) alcohol per week ( One unit alcohol equal 250 mL beer lager , one glass wine , 20 mL spirit ) Smoking 20 cigarette per day inability refrain smoking inhouse period Known hepatitis positive serological test hepatitis B surface antigen ( HBsAg ) hepatitis C antibodies HIV antibody Uncontrolled treated/untreated hypertension ( systolic blood pressure great equal 160 mmHg and/or diastolic blood pressure great equal 95 mmHg )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>